Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > URMC, Lighthouse Biosciences Awarded U.S. Patent for Diagnostic Technology

Abstract:
The University of Rochester Medical Center (URMC) has received a U.S. patent for a diagnostic technology that can rapidly and accurately screen for organisms such as bacteria and other infectious agents. Lighthouse Biosciences, LLC, a Rochester-based life sciences company, is the exclusive worldwide license holder of the technology.

URMC, Lighthouse Biosciences Awarded U.S. Patent for Diagnostic Technology

Rochester, NY | Posted on January 8th, 2009

The company's technology platform -- called NanoLantern -- is a novel method of identifying genetic sequences from biological samples, a process that can be used to detect any organism or genetic feature by identifying its unique DNA fingerprint. The NanoLantern consists of an array of DNA probes that can be programmed from a database of known genetic signatures to simultaneously screen for multiple individual targets using a single sample of blood, urine, cells, or other substance with organic content. The U.S. patent is being awarded for the process the technology uses to identify DNA sequences. The method, first developed by University of Rochester scientists in 2003, promises to be faster and more precise than other existing models.

"This patent represents an important milestone in developing the company's intellectual property portfolio," said Rand Henke, CEO of Lighthouse Biosciences. "It addresses a breakthrough method that will allow the company to design and make at a low cost a very wide range of probes for the detection of most pathogens."

The company is in the process of developing a prototype that consists of a series of disposable biosensor cartridges -- or labs on a chip -- that will be housed in a workstation that can be deployed in hospitals, doctor's offices, nursing homes, or any other health care setting.

While the technology has a wide array of potential applications in healthcare, agriculture, food safety, water quality, and national security, Lighthouse Biosciences is initially focused on the field of hospital-acquired infections (HAI). HAI are infections that patients receive during their care -- in a hospital or other health care facility such as a nursing home -- that are not related to any pre-existing medical condition. Despite extensive efforts in recent years to address the causes, HAI remain a massive burden on the U.S. health care system with more than 1 million annual cases and 90,000 associated deaths, all at a healthcare cost of $5.7 billion per year and at a cost to society of approximately $30 billion per year in the U.S.

One of the key challenges in combating HAI is the need to develop a system of surveillance that can identify these infections as early as possible. The current standard is to send potentially infectious samples out to a clinical laboratory for analysis and wait for the results. This process typically takes up to 2 to 3 days depending upon the proximity of the lab to the health care facility and the speed at which the lab can process the samples, a delay that can be an impediment to successful treatment. The NanoLantern technology has demonstrated the ability to provide results rapidly -- within 15 minutes -- and do so at the point of care.

The largest category of HAIs is urinary tract infections, which account for 40% of all infections. Lighthouse Biosciences, in cooperation with the URMC Departments of Urology and Microbiology and Immunology is currently conducting clinical studies to test the screening system at URMC's Strong Memorial Hospital.

The underlying technology for the company's NanoLantern(TM) platform was first developed by University of Rochester scientists Benjamin Miller, Ph.D., Todd Krauss, Ph.D. and Christopher Strohsahl, Ph.D. In addition to faculty appointments at the University, all three also hold corporate positions and/or equity positions in the company. Lighthouse Biosciences L.L.C., which was founded by the scientists in 2005, is based in the Lennox Tech Enterprise Center in Henrietta.

####

About The University of Rochester Medical Center (URMC)
One of the nation's top academic medical centers, the University of Rochester Medical Center (www.urmc.rochester.edu) forms the centerpiece of the University's health research, teaching, patient care, and community outreach missions. The Medical Center receives more than $230 million in external research funding per year, and the University of Rochester School of Medicine and Dentistry ranks in the top one-quarter of U.S. medical centers in federal research funding. The University's health care delivery network is anchored by Strong Memorial Hospital - a 739-bed, University-owned teaching hospital. As upstate New York's premier health care delivery network, patients benefit from the Medical Center's robust teaching and biomedical research programs.

About Lighthouse Biosciences, LLC

Lighthouse Biosciences, LLC is an early-stage, molecular in vitro diagnostic company located in Rochester, NY. Based on its proprietary NanoLantern(TM) platform, Lighthouse is developing breakthrough diagnostic solutions that are much faster, more accurate, simpler, and less expensive than currently used diagnostics. Additionally, the NanoLantern(TM) technology enables multiple tests on a single sample for simultaneous and very reliable results. Lighthouse solutions consist of "lab on chip" disposable cartridges that contain highly targeted detection probes and sample chemistry and a desktop reader workstation for preparing and presenting test results. Lighthouse expects its product solutions are small and simple enough to deploy throughout decentralized environments, like point-of-care healthcare locations, and are scalable to serve the high-volume needs of centralized laboratories.

For more information, please click here

Copyright © PR Newswire Association LLC.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Materials for the next generation of electronics and photovoltaics: MacArthur Fellow develops new uses for carbon nanotubes October 21st, 2014

Special UO microscope captures defects in nanotubes: University of Oregon chemists provide a detailed view of traps that disrupt energy flow, possibly pointing toward improved charge-carrying devices October 21st, 2014

Super stable garnet ceramics may be ideal for high-energy lithium batteries October 21st, 2014

Could I squeeze by you? Ames Laboratory scientists model molecular movement within narrow channels of mesoporous nanoparticles October 21st, 2014

Nanomedicine

Detecting Cancer Earlier is Goal of Rutgers-Developed Medical Imaging Technology: Rare earth nanocrystals and infrared light can reveal small cancerous tumors and cardiovascular lesions October 21st, 2014

Design of micro and nanoparticles to improve treatments for Alzheimers and Parkinsons: At the Faculty of Pharmacy of the UPV/EHU-University of the Basque Country encapsulation techniques are being developed to deliver correctly and effectively certain drugs October 20th, 2014

Non-Toxic Nanocatalysts Open New Window for Significant Decrease in Reaction Process October 19th, 2014

European Commission opens the gate towards the implementation of Nanomedicine Translation Hub October 16th, 2014

Announcements

Special UO microscope captures defects in nanotubes: University of Oregon chemists provide a detailed view of traps that disrupt energy flow, possibly pointing toward improved charge-carrying devices October 21st, 2014

Super stable garnet ceramics may be ideal for high-energy lithium batteries October 21st, 2014

Could I squeeze by you? Ames Laboratory scientists model molecular movement within narrow channels of mesoporous nanoparticles October 21st, 2014

Detecting Cancer Earlier is Goal of Rutgers-Developed Medical Imaging Technology: Rare earth nanocrystals and infrared light can reveal small cancerous tumors and cardiovascular lesions October 21st, 2014

Patents/IP/Tech Transfer/Licensing

Nanodevices for clinical diagnostic with potential for the international market: The development is based on optical principles and provides precision and allows saving vital time for the patient October 15th, 2014

Aculon Receives Patent for Application of Enhanced Bonding Layers on Titanium October 9th, 2014

harmaEngine will join Nanobiotix’ pivotal trial for NBTXR3 in Soft Tissue Sarcoma to accelerate its development in Asia-Pacific: PharmaEngine to make milestone payment to Nanobiotix in October 2014 to recognize the value created October 8th, 2014

‘Small’ transformation yields big changes September 16th, 2014

NanoNews-Digest
The latest news from around the world, FREE





  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE